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PreviewsIRGs, as well as nitric oxide, in the overall
mechanism of parasite killing in IFN-g-
activated macrophages? Why is the
defect in parasite killing resulting from
the silencing of Irgb6 not compensated
for by IFN-g-induced Irgm1 or Irgm3? In
addition, because Irgms and other IRGs
share the conserved region of Irgb6 tar-
geted by ROP18, why are these GTPases
not inactivated by ROP18 by the same
mechanism? In this regard, the current
and a recent study have reported that
ROP18 is indeed also able to phosphory-
late Irga6 and Irgb10 (Steinfeldt et al.,
2010). A further question concerns
whether RPO18 is sufficient and acts as
the sole determinant of virulence among
the diverse range of T. gondii strains and
whether other strain-specific kinases ex-
pressed in non-type I lineages play
a related role.
Interestingly, the remarkable difference
in the virulence among the three major
types of Toxoplasma in mice does not
appear to be recapitulated in humans.
Moreover, the host targets of ROP18 in
mice, Irga6, Irgb6, and Irgb10, are absent464 Cell Host & Microbe 8, December 16, 201in human cells (Hunn et al., 2010), sug-
gesting that this parasite virulence factor
may have coevolved with the IRG family.
Thus, it appears that ROP18 is utilized
by Toxoplasma to specifically counteract
the effector functions of the IRG family,
one of the most powerful host mecha-
nisms for defense against intracellular
pathogens documented in nonprimate
mammalian species.ACKNOWLEDGMENTS
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Oncogenic viruses infect many cells but rarely lead to tumorigenesis. In this issue of Cell Host & Microbe,
Nikitin et al. describe how a protective DNA damage response acts to suppress transformation in themajority
of cells latently infected with Epstein-Barr virus (EBV).Although genomic instability is a hallmark
of almost all human cancers, in most
cases it is still unclear how it arises and
contributes to tumorigenesis. In heredi-
tary cancers, germline mutations provide
an explanation for the initiation of genome
instability, but in sporadic cancers, the
molecular basis for the sourceof instability
is often unknown (Negrini et al., 2010).
Recent studies in cancer biology have
proposed that activation of the DNAdamage response (DDR) in early precan-
cerous lesions presents a barrier to tumor
progression (Halazonetis et al., 2008).
Activated oncogenes induce hyperprolif-
eration and replication stress, resulting in
DNA double-strand breaks (DSBs) that
induce the DDR (Figure 1). This response
activates the p53 tumor suppressor and
triggers cell-cycle arrest, senescence, or
apoptosis. The DDR in precancerous
lesions therebyacts asan inducible barrieragainst genomic instability, restricting
tumorigenesis (Bartkova et al., 2005; Gor-
goulis et al., 2005). This imposes a selec-
tive pressure for acquisition of mutations
that compromise the checkpoint, and
during cancer progression these defects
result in suppression of signaling, facili-
tating escape from apoptosis and senes-
cence (Halazonetis et al., 2008).
The DDR represents a cellular surveil-
lance network of signaling pathways that
Figure 1. The DNADamageResponse Is an Anticancer Barrier that Restricts Transformation
in EBV-Infected Cells
In the oncogene-induced DNA damage model of cancer development, activated oncogenes induce stall-
ing and collapse of DNA replication forks. The resulting DSBs generate a cellular DNA damage response
(DDR), characterized by kinase phosphorylation and checkpoint activation. This response leads to cell-
cycle arrest, senescence, and apoptosis, preventing cells from progressing to tumors (left side). In this
way, the DDR in precancerous lesions acts as an inducible barrier (boxed), restricting tumorigenesis. In
themajority of B cells latently infected with EBV, EBNA2 and latency III gene expression induces activation
of downstream oncogenes and an early period of hyperproliferation. The resulting DDR restricts long-term
outgrowth in the majority of cells. During LCL outgrowth, this DDR is attenuated by EBNA3C, acting either
directly on the DNA damage machinery or indirectly, by downregulating the activity of EBNA2.
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Previewssense the damage and sound alarms
to direct decisions between repair and
apoptosis (Jackson and Bartek, 2009).
When cells experience replication stress
or encounter DNA damage lesions, cell-
cycle checkpoints are activated toprevent
replication and segregation of damaged
genomes. The DDR kinase ATM phos-
phorylates a large number of protein
substrates, including p53, to activate
checkpoints and coordinate apoptosis.
ATM also directly phosphorylates the
checkpoint kinase Chk2 and mediatestumor suppression in response to DNA
damage. Activation of these DDRmarkers
is observed in precancerous lesions, and
continuous production of DSBs can be
detected prior to acquisition of p53 muta-
tions (Bartkova et al., 2005; Gorgoulis
et al., 2005). Therefore, these kinases
and their substrates serve as the gate-
keepers of the tumorigenesis barrier, and
cancer develops when the barrier is
breached through their inactivation.
Epstein-Barr virus (EBV) is linked to a
number of human malignancies. AlthoughCell Host & Microbe 8, Dmultiple viral proteins have been impli-
cated in promoting genomic instability
(Gruhne et al., 2009), little is known about
the cellular factors that govern the
outcome of infection. In this issue of Cell
Host & Microbe, a paper by Nikitin and
coworkers demonstrates that latent EBV
infection induces a cellular DDR that
acts to limit viral-mediated transformation
(Nikitin et al., 2010). In culture, EBV infec-
tion drives primary human B cells into
indefinitely proliferating lymphoblastoid
cell lines (LCLs). An initial wave of expres-
sion from viral and cellular genes leads to
proliferation of infected cells, but only
a small percentage of cells progress to
become LCLs. In these cells, EBV estab-
lishes a latent infection, characterized
by expression of a limited subset of
viral genes. These include Epstein-Barr
nuclear antigens (EBNAs) 1, 2, 3A, 3B,
3C, leader protein (EBNA-LP) and latent
membrane proteins (LMPs) 1, 2A, and
2B. Only EBNAs 1, 2, and 3C and LMP1
are essential for transformation of B cells.
Different stages of EBV latency have been
defined, and expression of EBNAs 2, 3, 4,
5, and 6 characterizes the most advanced
stage, termed latency III. Nikitin et al.
examined latent infections of primary
B cells by a transforming strain of EBV
and observed activation of checkpoint
markers (Figure 1). Induction of the EBV-
induced DDR was not due to lytic gene
expression or latent EBV DNA but
required EBNA2 and latency III gene
expression. Signaling correlated with a
virally induced state of cellular hyperpro-
liferation at early times postinfection,
reminiscent of the DDR activated by
S phase-promoting cellular oncogenes
(Bartkova et al., 2005).
If the DDR does indeed act as an anti-
cancer barrier active in early tumorigen-
esis, oncogenic viruses that induce trans-
formation must be able overcome this
barrier. In the present study, Nikitin et al.
suggest that the EBV-induced DDR is
attenuated during outgrowth of the
LCLs. Microarray studies confirmed that
an ATM-dependent p53 target signature
was induced in EBV-infected cells, but
that activated genes were subsequently
repressed in the transition from early
proliferating cells to established LCLs.
Analyzing viral gene expression at various
times postinfection, Nikitin et al. detected
a shift in the relative ratio of viral proteins
as LCL outgrowth began. The switchecember 16, 2010 ª2010 Elsevier Inc. 465
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would be expected to induce changes
in expression of host target genes. This
was seen with EBNA2 targets, which
were highly induced in the early cell divi-
sions after infection but were subse-
quently attenuated through LCL out-
growth. Multiple EBV proteins have been
suggested to affect cellular DNA damage
pathways (Gruhne et al., 2009). In the
current study, infections with virus lacking
EBNA3C demonstrated that this viral
protein was required for attenuation of
the host DDR (Nikitin et al., 2010), in
keeping with its elevated expression
during LCL outgrowth. EBNA3C displays
a plethora of diverse functions that could
contribute to the diminution of the DDR
during LCL outgrowth, including inhibition
of EBNA2-activated transcription, down-
regulation of Chk2, and repression of
p53 activity. Therefore, as EBV attenuates
the genotoxic and growth-suppressive
signaling pathway it has induced, the
outgrowth of genetically stable LCLs is
enabled. This model highlights how dys-
regulation of host or EBV latent gene
expression could lead to tumorigenesis.
A critical balance between latent onco-
protein-driven hyperproliferation, host
gene expression, and stable proliferative
signals in LCLs is required to maintain
the activated, immortalized state.
Since ATM and Chk2 are known to be
important regulators of the DNA damage
antitumor response, Nikitin et al. explored
whether inhibiting these kinases allowed
the virus to bypass the protective barrier.
Strikingly, when PBMCs were simulta-
neously infected with EBV and treated
with small-molecule inhibitors of ATM
or Chk2, transformation efficiency in-
creased. EBV-infected cells were most
sensitive to the inhibitors during the hy-
perproliferative period, indicating that an
early period of growth suppression medi-
ated by the DDR restricts transformation.
The paper by Nikitin et al. raises a
number of questions. Among these are
the mechanism by which EBNA2 acti-
vates the DDR and whether it requires
additional viral proteins. A hint comes
from the observation that S phase-
promoting oncoproteins are among the466 Cell Host & Microbe 8, December 16, 201targets of EBNA2. For example, c-Myc
and the genes it activates were highly
induced in early cell divisions and then
attenuated through LCL outgrowth. Since
ATM is known to be involved in suppress-
ing c-Myc oncogenesis, these data
support the hypothesis that it is acute
oncogenic stress early after EBV infection
that leads to hyperproliferation and DNA
damage signaling. The mechanism and
rationale for EBNA3C attenuating DNA
damage signaling as LCLs emerge also
remains to be determined. It is possible
that EBNA3C regulates EBNA2 induction
of the DDR to prevent viral clearance
or apoptosis, and any effects on the
efficiency of transformation are merely
a secondary outcome. Furthermore,
even with ATM and Chk2 inhibitors, the
transformation efficiency of EBV-infected
PBMCs remains low, suggesting that
additional mechanisms exist to restrict
viral-mediated transformation.
It was previously known that lytic EBV
infection induces ATM activation and
phosphorylation of downstream sub-
strates. Cellular DNA damage proteins
accumulate in viral replication compart-
ments, but preventing their activation
does not overtly affect viral replication
(Kudoh et al., 2005). The current study
focuses on latent EBV, adding an
additional layer of complexity to the inter-
action of this virus with the cellular DNA
damage machinery. Like EBV, many
viruses have evolved complex and multi-
faceted relationships with the cellular
DNA damage proteins (Lilley et al.,
2007), highlighting the fundamental
nature of this interface. The related onco-
genic herpesvirus, Kaposi’s sarcoma
herpesvirus (KSHV), has a strikingly
similar interaction with the DDR pathway
(Koopal et al., 2007). Like EBV, oncogenic
stress caused by a KSHV latent viral
protein induces DNA damage signaling
and antiproliferative checkpoints in an
early population of hyperproliferating
cells. Other transforming viruses such
as the human T-lymphotropic virus
(HTLV-1) and adenovirus also encode
proteins that promote hyperproliferation
and activate DNA damage markers (Lilley
et al., 2007). It will be interesting to see if0 ª2010 Elsevier Inc.the innate tumor suppressor function
proposed for the DDR in the current study
is a paradigm for regulation of transforma-
tion by other oncogenic viruses and
whether these observations in cell culture
are relevant to viral-induced tumorigen-
esis in vivo.
In conclusion, the study by Nikitin et al.
demonstrates that the oncogene-induced
DNA damage model for cancer develop-
ment is not restricted to controlling
aberrant cellular tumorigenic events. It
raises the possibility that this anticancer
pathway may have evolved, at least in
part, as a protective mechanism against
viruses. This study presents another
example of the intricate balance achieved
by viruses in their interactions with
protective host pathways and also high-
lights the importance of controlled
temporal feedback to regulate viral func-
tions as infection progresses.REFERENCES
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